UroGen Pharma (URGN) Cash & Equivalents (2016 - 2026)

UroGen Pharma (URGN) has 11 years of Cash & Equivalents data on file, last reported at $110.0 million in Q1 2026.

• Quarterly Cash & Equivalents rose 5.7% year-over-year to $110.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $110.0 million (up 5.7% YoY) and the FY2025 annual result came in at $110.7 million, down 35.61% from the prior year.
• Cash & Equivalents eased to $110.0 million in Q1 2026, from $110.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $220.0 million in Q2 2024 to a low of $20.1 million in Q2 2023.
• A 5-year average of $97.8 million and a median of $104.0 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents slumped 65.33% — and 2024, when it soared 992.92%.
• Tracing URGN's Cash & Equivalents over 5 years: stood at $55.4 million in 2022, then jumped by 71.46% to $95.0 million in 2023, then jumped by 81.04% to $172.0 million in 2024, then plunged by 35.61% to $110.7 million in 2025, then dropped by 0.7% to $110.0 million in 2026.
• The last three Cash & Equivalents figures came in at $110.0 million (Q1 2026), $110.7 million (Q4 2025), and $90.0 million (Q3 2025), per Business Quant data.